2-bromo-1-[4-[4-(2-bromoacetyl)phenyl]phenyl]ethanone

We are 2-bromo-1-[4-[4-(2-bromoacetyl)phenyl]phenyl]ethanone CAS:4072-67-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:    2-bromo-1-[4-[4-(2-bromoacetyl)phenyl]phenyl]ethanone
CAS.NO:4072-67-7
Synonyms:1,1-(1,1-Biphenyl)-4,4-diylbis(2-bromoethan-1-one)
1,1'-(4,4'-Biphenyldiyl)bis(2-bromoethanone)

Molecular Formula: C16H12Br2O2
Molecular Weight:396.07300

Physical and Chemical Properties:
Density: 1.622g / cm3
Boiling point: 464.8ºC at 760 mmHg
Flash point: 121.3ºC
Refractive index: 1.625

Specification:
Appearance: White crystalline powder
Purity:≥98.0%
Identification:
A .H-NMR:Comply with the structure
B.LC-MS:Comply with the structure
C.The IR spectrum of sample should be identical with that ofreference standard
D.HPLC-ESI-MS
The retention time of the major peak in the chromatogram ofthe Assay preparation corresponds to that in the chromatogram of the Standard preparation, as obtained inthe Assay.
Crystallization:meets the requirements.
Loss on drying:≤0,5%
Heavy metals:≤10 ppm
Water:≤1.0%
Sulphated ash:≤0. 2%, determined on 1.0 g.
Relatedsubstances:
Unspecified impurities: for each impurity≤0.10%
Total Impurity≤1.0%
Purity:≥99.0%
Assay:99.0%~ 101.0% (anhydrous substance).

Packing:
 25kgs packaging Fiber drum outside and plastic bag inside,1-25kgs packaging aluminium bag outside and double plastic bag inside.
Storage:Store in a well-closed container away from moisture.
Application: It can be used to synthesize Daclatasvir which inhibits the HCV protein NS5A, and thus can be used as a drug candidate for the treatment of hepatitis C (HCV).Intermediates of Daclatasvir CAS:1009119-64-5

2-bromo-1-[4-[4-(2-bromoacetyl)phenyl]phenyl]ethanone


Related News: “Our collaboration with Mankind demonstrates our commitment towards providing novel, innovative treatment options for efficient diabetes management,” Glenmark Pharmaceuticals President, India Formulations, Middle East and Africa Sujesh Vasudevan said.2-hidroxi-3-metil-2-ciclopentenona CAS:80-71-7 Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 250 issued patents and 150 pending patent applications.5'-desoxi-5-fluorocitidina CAS:66335-38-4 Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).4-Isopropoxylphenylboronic acid CAS:153624-46-5 Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).

Related Products
Product Name
2-Fluoro-5-(trifluoromethyl)aniline View Details
3-Chloro-4-Iodopyridine View Details
4-pyridin-4-ylbutanoic acid,hydrochloride View Details
nervonic acid manufacturer trans-Hexahydroisobenzofuran-1,3-dione manufacturer 9H-fluoren-9-ylmethyl N-[(2S,3S)-1-hydroxy-3-methylpentan-2-yl]carbamate manufacturer 2-Chloro-3-nitrotoluene manufacturer 2-Hydroxy-6-methylpyridine manufacturer